Guobang Pharma Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.038x

Guobang Pharma Ltd cash flow conversion efficiency. Based on the latest financial reports, Guobang Pharma Ltd (605507) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥311.27 Million ≈ $45.55 Million USD) by net assets (CN¥8.28 Billion ≈ $1.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Guobang Pharma Ltd (2017–2025)

Cash flow conversion efficiency of Guobang Pharma Ltd from 2017 to 2025. This chart illustrates how Guobang Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 605507 live share price for real-time trading data and today's change.

Guobang Pharma Ltd Cash Flow Conversion Ratio Explained

Guobang Pharma Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Guobang Pharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guobang Pharma Ltd ranked by their cash flow conversion efficiency. Also see 605507 market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Greif Bros Corporation NYSE:GEF	0.024x
Dime Community Bancshares, Inc. NYSE:DCOM	0.037x
Baoding Heavy Industry Co Ltd SHE:002552	0.122x
Wuhan Yangtze Communication Industry Group Co Ltd SHG:600345	-0.001x
A10 Network NYSE:ATEN	0.122x
Star Petroleum Refining Co Ltd BK:SPRC	-0.019x
Sonos Inc NASDAQ:SONO	-0.170x
Ruentex Industries Ltd TW:2915	0.003x

Annual Cash Flow Conversion Efficiency for Guobang Pharma Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Guobang Pharma Ltd from 2017 to 2025. Review 605507 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥8.56 Billion ≈ $1.25 Billion	CN¥559.28 Million ≈ $81.84 Million	0.065x	-25.49%
2024-12-31	CN¥8.05 Billion ≈ $1.18 Billion	CN¥706.41 Million ≈ $103.37 Million	0.088x	+26.26%
2023-12-31	CN¥7.44 Billion ≈ $1.09 Billion	CN¥516.76 Million ≈ $75.62 Million	0.069x	-51.12%
2022-12-31	CN¥7.15 Billion ≈ $1.05 Billion	CN¥1.02 Billion ≈ $148.82 Million	0.142x	+611.99%
2021-12-31	CN¥6.35 Billion ≈ $928.57 Million	CN¥-176.18 Million ≈ $-25.78 Million	-0.028x	-111.84%
2020-12-31	CN¥3.27 Billion ≈ $479.11 Million	CN¥767.70 Million ≈ $112.34 Million	0.234x	+39.13%
2019-12-31	CN¥2.62 Billion ≈ $382.78 Million	CN¥440.86 Million ≈ $64.51 Million	0.169x	-19.35%
2018-12-31	CN¥2.59 Billion ≈ $379.31 Million	CN¥541.68 Million ≈ $79.27 Million	0.209x	+211.60%
2017-12-31	CN¥2.21 Billion ≈ $323.00 Million	CN¥148.03 Million ≈ $21.66 Million	0.067x	--

About Guobang Pharma Ltd

SHG:605507 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.80 Billion

CN¥12.29 Billion CNY

Market Cap Rank

#6303 Global

#1215 in China

Share Price

CN¥15.71

Change (1 day)

-0.63%

52-Week Range

CN¥14.50 - CN¥29.25

All Time High

CN¥43.71